These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 10081351)

  • 21. Prevalence of HBV, HCV, HIV-1, 2 and HTLV-I/II infections among blood donors in a teaching hospital in the Central region of Saudi Arabia.
    El-Hazmi MM
    Saudi Med J; 2004 Jan; 25(1):26-33. PubMed ID: 14758374
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of antibodies to human T-lymphotropic virus types I and II in volunteer blood donors and high-risk groups in northwestern Greece.
    Dalekos GN; Zervou E; Karabini F; Elisaf M; Bourantas K; Siamopoulos KC
    Transfusion; 1995 Jun; 35(6):503-6. PubMed ID: 7770902
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of HTLV-I/II infection in blood donors in Buenos Aires.
    Gutfraind Z; Blejer JL; Saguier MC; Gómez Carretero ML; Pirola DA; Carreras Vescio LA
    Medicina (B Aires); 1995; 55(4):295-9. PubMed ID: 8728867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human T-lymphotropic virus infection: is it a threat?
    Zaaijer H
    Transplant Proc; 1996 Oct; 28(5):2940. PubMed ID: 8908133
    [No Abstract]   [Full Text] [Related]  

  • 25. Saudi National Guard donor screening for human T cell lymphotropic virus I/II: time to use molecular biology techniques.
    Balkhy HH; Memish ZA; Abed E; Qasem L; Amer AB; Masoud S; Hajeer AH
    Mil Med; 2004 Mar; 169(3):251-3. PubMed ID: 15080248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of HTLV-I and -II in Scottish blood donor samples and archive donations.
    Davidson F; Lycett C; Jarvis LM; Kerr D; Lumley S; Petrik J; Dow BC
    Vox Sang; 2006 Oct; 91(3):231-6. PubMed ID: 16958835
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prevalence of HTLV-I/II infection among blood donors in Santa Fe Province, Argentina].
    Brun RO; Astarloa L; Salomon HE; Biglione MM
    Medicina (B Aires); 2004; 64(2):125-8. PubMed ID: 15628298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lookback study of HTLV-1 and 2 seropositive donors and their recipients in Belo Horizonte, Brazil.
    Namen-Lopes MS; Martins ML; Drummond PC; Lobato RR; ; Carneiro-Proietti AB
    Transfus Med; 2009 Aug; 19(4):180-8. PubMed ID: 19706135
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The outcome of donor screening for human T-cell lymphotropic virus infection in The Netherlands.
    Prinsze FJ; Zaaijer HL
    Vox Sang; 2012 Apr; 102(3):198-203. PubMed ID: 21895678
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [HTLV-I/II seroprevalence and risk factors associated with infection in a blood donor population in Córdoba, Argentina].
    Gallego S; Maturano E; Recalde A; Gastaldello R; Sileoni S; Bepre H; Medeot S
    Rev Argent Microbiol; 2001; 33(3):182-6. PubMed ID: 11594010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Residual risk of retrovirus transmission by transfusions].
    Soriano V; Heredia A
    Rev Clin Esp; 1995 Jun; 195(6):418-24. PubMed ID: 7644794
    [No Abstract]   [Full Text] [Related]  

  • 32. [Determination of anti-HTLV-I/II antibodies: Experience in 28,897 blood donations in Buenos Aires].
    Blejer JL; Saguier MC; Salamone HJ; Carreras LA
    Sangre (Barc); 1995 Dec; 40(6):447-51. PubMed ID: 8850226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Retrovirus and blood transfusion].
    Barrera JM; Ercilla MG; Gil BC
    Sangre (Barc); 1993 Jun; 38(3):187-92. PubMed ID: 8105545
    [No Abstract]   [Full Text] [Related]  

  • 34. The introduction of anti-HTLV testing of blood donations and the risk of transfusion-transmitted HTLV, UK: 2002-2006.
    Davison KL; Dow B; Barbara JA; Hewitt PE; Eglin R
    Transfus Med; 2009 Feb; 19(1):24-34. PubMed ID: 19302452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The epidemiology of the human T-cell lymphotrophic virus type I and type II: etiologic role in human disease.
    Manns A; Blattner WA
    Transfusion; 1991 Jan; 31(1):67-75. PubMed ID: 1986467
    [No Abstract]   [Full Text] [Related]  

  • 36. [Prevalence of HTLV-I and HTLV-II infection in Puglia].
    Quarto M; Chironna M; Germinario C; Lopalco PL; Barbuti S
    Ann Ig; 1996; 8(6):649-55. PubMed ID: 9312232
    [No Abstract]   [Full Text] [Related]  

  • 37. [Infection by human T-cell lymphotropic virus type I/II in polytransfused patients in the state of Yucatán, Mexico].
    González-Martínez P; Castro-Sansores C; Vivas-Rosel ML; Góngora-Biachi RA
    Sangre (Barc); 1994 Feb; 39(1):45-8. PubMed ID: 7910984
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HTLV-I/II prevalence in different geographic locations.
    Vrielink H; Reesink HW
    Transfus Med Rev; 2004 Jan; 18(1):46-57. PubMed ID: 14689377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prevalence of human T-lymphotropic virus, Type 1 and 2 in blood donors and patients with sexually transmissible diseases in Surinam].
    Alberga H; Goubau P; Desmyter J; Carton H
    Ned Tijdschr Geneeskd; 1996 Aug; 140(33):1689-92. PubMed ID: 8830293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Investigation of anti-HTLV I/II seroprevalence in healthy blood donors in Izmir region, Turkey].
    Sertöz R; Turhan A; Bozkurt H; Samlıoğlu P; Değirmenci A; Aydınok Y; Erensoy S
    Mikrobiyol Bul; 2010 Oct; 44(4):579-84. PubMed ID: 21063970
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.